ReviewCells2024
Evolving Paradigms in Sepsis Management: A Narrative Review.
Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Sepsis biomarkers: recent advances and future perspectives.Frontiers in immunology · 2026Review
- Extracellular caspase-1: a critical inducer and a therapeutic target of lung injury in gut ischemia-reperfusion.Frontiers in immunology · 2026Article
- Article
- Epigenetic metabolite lipid nanoparticles alleviate venous thrombosis via bone marrow reprogramming.Blood vessels, thrombosis & hemostasis · 2025Article
- Predictive value of combined inflammatory markers for septic cardiomyopathy: a retrospective study.BMC infectious diseases · 2025Article
- Advancing traditional Chinese medicine for sepsis-challenges beyond clinical evidence.Critical care (London, England) · 2025Article
- [Specialty-specific knowledge as prerequisite for effective treatment of critically ill patients].Chirurgie (Heidelberg, Germany) · 2025Article
- Mesenchymal stem/stromal cells as a therapeutic for sepsis: a review on where do we stand?Stem cell research & therapy · 2025Review
- Personalized Nutrition Strategies for Patients in the Intensive Care Unit: A Narrative Review on the Future of Critical Care Nutrition.Nutrients · 2025Review
- Noninvasive Vagus Nerve Electrical Stimulation for Immune Modulation in Sepsis Therapy.Journal of the American Chemical Society · 2025Article
- Bacteria and host: what does this mean for sepsis bottleneck?World journal of emergency medicine · 2025Review
- Interpretable machine learning-based prediction of 28-day mortality in ICU patients with sepsis: a multicenter retrospective study.Frontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Sepsis, a condition characterized by life-threatening organ dysfunction due to a dysregulated host response to infection, significantly impacts global health, with mortality rates varying widely across regions. Traditional therapeutic strategies that target hyperinflammation and immunosuppression have largely failed to improve outcomes, underscoring the need for innovative approaches. This review examines the development of therapeutic agents for sepsis, with a focus on clinical trials addressing hyperinflammation and immunosuppression. It highlights the frequent failures of these trials, explores the underlying reasons, and outlines current research efforts aimed at bridging the gap between theoretical advancements and clinical applications. Although personalized medicine and phenotypic categorization present promising directions, this review emphasizes the importance of understanding the complex pathogenesis of sepsis and developing targeted, effective therapies to enhance patient outcomes. By addressing the multifaceted nature of sepsis, future research can pave the way for more precise and individualized treatment strategies, ultimately improving the management and prognosis of sepsis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.